Abbott Laboratories Corporation

Abbvie Inc.

Gruenenthal Gmbh

Basf Aktiengesellschaft

Grunenthal Gmbh

Ulrich Reinhold

Laman L Alani

Gunther Berndl

Bernd Liepold

Soumojeet Ghosh

Joerg Breitenbach

Joerg Rosenberg

Marc Schiller

Eva Wulsten

J&ouml;rg Breitenbach

Ulrike Bertram

Sabine Karine Katrien Inghelbrecht

Ulrich Feil

Roger Carolus Augusta Embrechts

Klaus Schiene

Thomas Christoph

Thomas Kessler

Jörg Breitenbach

Stephan Kothrade

Jörg Rosenberg

Petra Bloms-Funke

Werner Maier

Armin Lange

J&ouml;rg Rosenberg

J&uuml;rgen Zeidler

Harald Krull

Jöerg Rosenberg

Jeorg Rosenberg

Carlos Van Hemelrijck

Wolfgang Prange

Angelika Ellermann

Stefanie Straub

Gunther Derndl

Eva Cornelia Wulsten

Carmen Hartmann

Christian Grosse

Sabine Karine Inghelbrecht

Roger Carolus Embrechts

Joeerg Rosenberg

Jorg Breitenbach

Norbert Poellinger

Anika-Anina Philipp

Annette Grave

An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.

Aqueous pharmaceutical formulation of tapentadol for oral administration

The invention relates to an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof, wherein the concentration of Tapentadol is within the range of from 0.10 to 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; and wherein the pH value of the composition is buffered and within the range of from 4.0 to 6.0. The invention also relates to a container comprising the pharmaceutical composition and a process for the preparation thereof. The invention also relates to a kit comprising the contained according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in pediatric patients.

Stable formulation for parenteral administration of tapentadol

The invention relates to an an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof; wherein the concentration of Tapentadol is greater than 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; wherein the composition comprises a buffer system; and wherein the pH value of the composition is within the range of from greater than 3.0 to less than 6.7. The invention also relates to a kit comprising the composition according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in adult patients.

Stable formulation for parenteral administration of Tapentadol

A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.

Semisolid aqueous pharmaceutical composition containing tapentadol

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50&#xb0; C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Solid pharmaceutical dosage form

The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

Solid pharmaceutical dosage formulation

Solvent-free noncrystalline bioactive substances are prepared from the corresponding crystalline bioactive substances in an extruder by melting the substances in the extruder under reduced pressure and in the absence of auxiliaries, cooling and comminuting.

Method for producing solvent-free noncrystalline biologically active substances

A process for producing solid dosage forms, in which (i) a plastic mixture of at least one pharmacologically acceptable polymeric binder with a K value of more than 75, at least one pharmaceutical active ingredient and, where appropriate, conventional pharmaceutical additives is prepared and (ii) the plastic mixture is shaped to the required dosage form, with step (i) being carried out under conditions of temperature and shear energy input such that the reduction in molecular weight of the polymeric binder, expressed as the difference in the K value, is less than 15 is described.

Process for producing solid dosage forms

Growing community of inventors

Heidelberg, Germany

Ulrich Reinhold